长期人肝组织芯片系统综合评估利福平介导的转运体和药物代谢酶诱导
本研究利用来自三名供体的转运体认证冷冻保存原代人肝细胞,在肝组织芯片(LTC)中循环流动培养7天,给予或不给予10 μM利福平处理。结果显示利福平在蛋白水平诱导多种转运体和酶,且转运体mRNA与蛋白诱导模式常不一致,提示存在PXR之外调控机制;五种CYP酶mRNA-蛋白-活性匹配测量也显示诱导幅度差异。
要点
- LTC可长期同时评估转运体与DME的mRNA、蛋白及活性诱导。
- 利福平在蛋白水平诱导OATP2B1、P-gp、CYP3A4、CYP2C19和UGT1A4。
- 转运体mRNA与蛋白诱导模式常不一致,提示非PXR调控机制。
核心结论
- LTC能够整合评估mRNA、蛋白和活性测量以及胆汁酸谱和胞内药物暴露,可能改善对诱导过程机制的理解。
研究设计与样本
- 使用来自三名供体的转运体认证冷冻保存原代人肝细胞,在LTC中循环流动培养7天,给予或不给予10 μM利福平处理。
主要发现
- 利福平在蛋白水平诱导OATP2B1、P-糖蛋白、CYP3A4、CYP2C19和UGT1A4。
- 转运体mRNA与蛋白诱导模式在许多情况下不同,提示PXR介导激活之外的调控机制。
- 五种CYP酶的mRNA-蛋白-活性匹配测量显示利福平介导的诱导幅度存在差异。
- 利福平改变胆汁酸组成,增加牛磺酸结合胆汁酸并诱导胆汁酸相关基因。
- 测得的胞内利福平浓度与实验所用培养基浓度差异显著。
临床怎么用
- LTC可作为长期评估转运体和DME介导的诱导风险的新方法学(NAM)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rifampicin is a prototypical clinical inducer used in drug-drug interaction (DDI) studies. However, the clinical relevance and predictability of rifampicin-mediated hepatic transporter induction remain poorly defined. Conventional hepatocyte culture models fail to capture clinically relevant regulation of transporters and drug-metabolizing enzymes (DMEs), particularly at the protein level. In this study, we characterized a liver tissue chip (LTC) as a new approach methodology (NAM) for long-term transporter- and DME-mediated induction risk assessment. Transporter-certified® cryopreserved primary human hepatocytes from three donors were cultured in the LTC under recirculating flow with or without 10 μM rifampicin for 7 days. The LTC facilitated simultaneous mRNA-protein quantification for transporters and mRNA-protein-activity profiling for cytochrome P450s (CYPs) within individual chips across treatment and control conditions. In addition, extracellular bile acid profiling and intracellular rifampicin concentrations were measured by LC-MS/MS. Rifampicin induced multiple transporters and enzymes at the protein level, including organic anion transporting polypeptide (OATP)2B1, P-glycoprotein, CYP3A4, CYP2C19, and uridine 5'-diphospho-glucuronosyltransferase (UGT)1A4. Induction patterns differed between transporter mRNA and protein in many cases, suggesting regulatory mechanisms beyond PXR-mediated activation. Matched mRNA-protein-activity measurements of five CYP enzymes also revealed discrepancies in rifampicin-mediated induction magnitude. Rifampicin altered bile acid composition, increasing taurine-conjugated bile acids and inducing bile acid-related genes. Measured intracellular rifampicin concentrations differed substantially from experimentally employed media concentrations. Overall, these findings demonstrate that the LTC enables integrated assessment of mRNA, protein, and activity measurements in addition to bile acid profiles and intracellular drug exposure, which may improve mechanistic understanding of induction processes.
引用
- Hartauer ME, Lanphier RM, Ohri S, et al. Integrated assessment of rifampicin-mediated induction of transporters and drug-metabolizing enzymes in a long-term human liver tissue chip system. Clin Pharmacol Ther. 2026. PMID: 42596617. doi:10.1002/cpt.70418
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。